The PLATFORM Trial: An Insight into the Improved Value of Using FFR_{CT} for Reduction of Invasive Angiographic Procedures

Zhonghua Sun*

Department of Medical Radiation Sciences, Curtin University, GPO Box U1987 Perth, WA 6845, Australia

Coronary CT Angiography (CCTA) has been widely used as a reliable non-invasive modality for the diagnosis of Coronary Artery Disease (CAD) due to its improved spatial and temporal resolution.1-5 For patients with low to intermediate pre-test probability of CAD, CCTA is used as an effective gatekeeper for determination of downstream testing, such as invasive coronary angiography or functional imaging.6 However, CCTA is mainly an anatomic test with excellent visualization of coronary anatomical structures and detection of coronary lumen stenosis, while providing little functional information of the coronary lesions. Despite high sensitivity and negative predictive value, CCTA has been reported to have moderate specificity and positive predictive value due to the high percentage of false positive rates, and this is especially apparent in the assessment of coronary arteries with heavy calcification. Studies have shown the limited diagnostic value of CCTA in diagnosing highly calcified coronary plaques.7-11 Thus, an imaging technique able to detect ischemia-producing lesions is of paramount importance since coronary stenosis does not always translate to functional significance. Clinical decision making of whether patients should proceed to a revascularization procedure is based on the predictive functional effect of coronary stenosis, because no prognostic benefit of revascularization has been reported in the coronary lesions without functional significance.12,13

In recent years, a great interest has been shown in the investigation of diagnostic performance of non-invasive Fractional Flow Reserve derived from coronary CT angiography (FFR_{CT}). The scientific basis for non-invasive quantification of FFR_{CT} has been well described in the literature.14 FFR_{CT} is computed by performing computational fluid dynamics modelling after image segmentation of coronary arteries and ascending aorta. The invasive FFR technique is conducted by using a pressure catheter to assess the rate of maximal myocardial blood flow through a coronary stenotic lesion in relation to the flow through the normal aorta in a hyperemic state.15-17 The FFR is a lesion-specific technique and is widely used as the reference test for assessment of the functional significance of a coronary stenosis. According to the Fractional Flow reserve versus angiography for multivessel evaluation (FAME) trials, FFR-guided percutaneous coronary intervention has been shown to result in lower rate of major adverse cardiac events when compared to visual estimation from invasive coronary angiography or best available medical therapy alone.18,19 However, invasive FFR is rarely performed in clinical practice, thus, a non-invasive method combining both anatomic and functional data to determine the hemodynamic significance of coronary lesions could serve as an alternative to invasive FFR for improvement of patient care and clinical outcomes.

In the PLATFORM prospective multicentre trial, Douglas, et al. compared the clinical outcomes of symptomatic patients with an intermediate likelihood of obstructive CAD, who were assigned to undergo either the planned usual care testing or CCTA/FFR_{CT} testing.20 A total of 584 patients were recruited from 11 clinical sites with 287 receiving usual testing and 297 receiving CCTA/FFR_{CT} testing. The 90-day follow-up visits were reported in this study to
determine the cardiac event rates. The authors reported that non-obstructive CAD was found at Invasive Coronary Angiography (ICA) in 73% of the patients in the usual care group with intended ICA. In contrast, non-obstructive CAD was found at ICA in 12% of the patients in the CCTA/FFR<sub>CT</sub> group, which is significantly lower than that observed in the usual care group (p<0.0001) (Figure 1). Among those with planned non-invasive testing, no significant difference was found in the rates of non-obstructive CAD at ICA between the two groups (6.0 usual care vs. 12.5% CCTA/FFR<sub>CT</sub>, p=0.95) (Figure 1). There were no significant differences in cardiac events between these two groups. The authors concluded that use of CCTA/FFR<sub>CT</sub> can be more effectively triage patients than the use care approach for invasive procedures since ICA was cancelled in 61% patients based on the results of CCTA/FFR<sub>CT</sub>.

There are 2 observations from Douglas’s study that bear discussion. First, improved diagnostic strategy has been achieved in patient managements based on analysis of CCTA/FFR<sub>CT</sub>, with a significantly low rate of ICA showing non-obstructive CAD. This further verifies the advantage of FFR<sub>CT</sub> over CCTA in the diagnostic assessment of coronary stenosis. According to a recently published randomized controlled PROMISE trial, coronary CTA was found to increase the rate of invasive catheterization by 50% compared with functional testing.21 Clinical value of FFR<sub>CT</sub> in comparison with CCTA has been reported in three multicenter trials, Diagnosis of Ischemia-Causing Coronary Stenoses by Non-invasive FFR Computed from Coronary Computed Tomographic Angiograms (DISCOVER-FLOW), Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography (DeFACTO), and NeXtSeps (NXT) trials.22-24 Findings of these trials confirm that FFR<sub>CT</sub> is superior to CCTA for the diagnosis of ischemia-causing lesions on both per-patient and per-vessel analysis as determined by an invasive FFR the reference standard. Table 1 shows the diagnostic value of FFR<sub>CT</sub> versus CCTA in stable patients with suspected CAD based on the analysis of these three trials.

![Figure 1: Determination of the rate of invasive catheterization without obstructive coronary artery disease. NI: Non-invasive; ICA: Invasive Coronary Angiography; Obs CAD: Obstructive Coronary Artery Disease; FFR<sub>CT</sub>: Computation of fractional flow reserve from coronary computed tomographic angiography data.](image)

There are 2 observations from Douglas’s study that bear discussion. First, improved diagnostic strategy has been achieved in patient managements based on analysis of CCTA/FFR<sub>CT</sub>, with a significantly low rate of ICA showing non-obstructive CAD. This further verifies the advantage of FFR<sub>CT</sub> over CCTA in the diagnostic assessment of coronary stenosis. According to a recently published randomized controlled PROMISE trial, coronary CTA was found to increase the rate of invasive catheterization by 50% compared with functional testing.21 Clinical value of FFR<sub>CT</sub> in comparison with CCTA has been reported in three multicenter trials, Diagnosis of Ischemia-Causing Coronary Stenoses by Non-invasive FFR Computed from Coronary Computed Tomographic Angiograms (DISCOVER-FLOW), Determination of Fractional Flow Reserve by Anatomic Computed Tomographic Angiography (DeFACTO), and NeXtSeps (NXT) trials.22-24 Findings of these trials confirm that FFR<sub>CT</sub> is superior to CCTA for the diagnosis of ischemia-causing lesions on both per-patient and per-vessel analysis as determined by an invasive FFR the reference standard. Table 1 shows the diagnostic value of FFR<sub>CT</sub> versus CCTA in stable patients with suspected CAD based on the analysis of these three trials.

<table>
<thead>
<tr>
<th>Diagnostic value</th>
<th>DISCOVER-FLOW&lt;sup&gt;22&lt;/sup&gt;</th>
<th>NXT&lt;sup&gt;24&lt;/sup&gt;</th>
<th>DeFACTO&lt;sup&gt;23&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Per-patient assessment</td>
<td>Per-vessel assessment</td>
<td>Per-patient assessment</td>
</tr>
<tr>
<td>CCTA≥ 50%</td>
<td>94</td>
<td>91</td>
<td>94</td>
</tr>
<tr>
<td>Sensitivity</td>
<td>25</td>
<td>40</td>
<td>34</td>
</tr>
<tr>
<td>Specificity</td>
<td>58</td>
<td>47</td>
<td>40</td>
</tr>
<tr>
<td>PPV</td>
<td>80</td>
<td>89</td>
<td>92</td>
</tr>
<tr>
<td>FFR&lt;sub&gt;CT&lt;/sub&gt; ≤ 0.80</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sensitivity</td>
<td>93</td>
<td>88</td>
<td>86</td>
</tr>
<tr>
<td>Specificity</td>
<td>82</td>
<td>82</td>
<td>79</td>
</tr>
<tr>
<td>PPV</td>
<td>85</td>
<td>74</td>
<td>65</td>
</tr>
<tr>
<td>NPV</td>
<td>91</td>
<td>92</td>
<td>93</td>
</tr>
</tbody>
</table>

PPV: Positive Predictive Value, NPV: Negative Predictive Value.

Table 1: Three multicenter trials comparing FFR<sub>CT</sub> with CCTA with invasive FFR as the gold standard.
Second, ICA examination is associated with high rate of non-obstructive CAD as shown in Figure 1. Although physicians’ angiographic interpretation of coronary stenosis has been reported to have substantial disagreement from quantitative coronary angiographic images,25,26 the visual readings in Douglas’s study were low (57%) as the findings of determining non-obstructive CAD in ICA patients were determined by quantitative coronary angiography. This further highlights the limitation of ICA as an anatomic test or a luminogram. The role of ICA is gradually diminishing as compared to other imaging modalities such as CCTA or intravascular ultrasound,27,28 which are able to look beyond the lumen and characterize plaque morphology or vessel wall, thus, enabling detection of vulnerable coronary plaques responsible for development of adverse cardiac events. ICA remains the gold standard for the detection of coronary stenosis, however, according to the PROSPECT, the largest prospective study to investigate the natural history of CAD,29 the majority of non-culprit lesions responsible for acute coronary syndrome at a median follow-up of 3.4 years were mild lesions with diameter stenosis of 32% at baseline angiographic examination. Therefore, combining anatomic with functional imaging modalities represents a future direction for determination of functional significance of coronary lesions.

In summary, the PLATFORM trial adds additional value to other two recently published randomized controlled trials involving diagnostic performance of CCTA in CAD, the PROMISE and SCOT-HEART trials.21,30 Like all large multicenter trials, PLATFORM has limitations. It is not a randomized controlled trial. Further, the sample size and short follow-up period (90 days) make it difficult to detect the impact on clinical outcomes. Further studies with inclusion of a large cohort at longer follow-up periods are warranted.

REFERENCES


14. Taylor CA, Fonte TA, Min JK. Computational fluid dynamics applied to cardiac computed tomography for noninvasive quantification of fractional flow reserve: scientific basis. *J Am Coll Cardiol*. 2013; 61: 2233-2241. doi: 10.1016/j.jacc.2012.11.083


